What are the side effects of Lorlatinib/lorlatinib?

Lorlatinib/Lorlatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) positive as measured by an FDA approved test. The recommended dose of lorlatinib is 100 mg orally administered once daily with or without food until disease progression or unacceptable toxicity occurs.

While taking lorlatinib/While taking lorlatinibSwallow the tablet whole, Do not chew, crush, or split the tablet, Do not take the tablet if it is broken, broken, or incomplete. Take at the same time each day, if you miss a dose, take the missed dose unless the next dose is due within 4 hours and do not take two doses at the same time to make up for a missed dose. If vomiting occurs after taking lorlatinib, do not take additional doses but continue with the next scheduled dose.

Lorlatinib/LorlatinibThe most common (Incidence≥20%)Adverse reactions and Grade 3-4 laboratory abnormalities were edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, dyspnea, arthralgia, diarrhea, mood effects, hypercholesterolemia, hypertriglyceridemia, and cough. Avoid coadministration of lorlatinib with CYP3A substrates as minimal concentration changes may result in serious treatment failure. Avoid concomitant use of lorlatinib with P-gp substrates as minimal concentration changes may result in serious treatment failure. The generic version of lorlatinib is available at a more favorable price, ranging from 3 to 5 thousand per box. The Turkish version of the original drug is about more than 10,000 per box, and there are many versions of loratinib. Patients can choose the drug by themselves according to the actual situation. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.